{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:04:44Z","timestamp":1789009484112,"version":"build-2803163510"},"reference-count":79,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.hoc.2020.06.009","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T08:01:47Z","timestamp":1596614507000},"page":"941-956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Blastoid Mantle Cell Lymphoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Preetesh","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.hoc.2020.06.009_bib1","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ajh.25487","article-title":"Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management","volume":"94","author":"Jain","year":"2019","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.009_bib2","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/03007995.2020.1742101","article-title":"Systematic literature review of the global burden of illness of mantle cell lymphoma","volume":"36","author":"Monga","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.hoc.2020.06.009_bib3","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020005289","article-title":"Genomic and epigenomic insights into the origin, pathogenesis and clinical behavior of mantle cell lymphoma subtypes","author":"Nadeu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.009_bib4","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2019002385","article-title":"Coding and non-coding drivers of mantle cell lymphoma identified through exome and genome sequencing","author":"Pararajalingam","year":"2020","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.hoc.2020.06.009_bib5","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","article-title":"Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features","volume":"72","author":"Navarro","year":"2012","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.009_bib6","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3324\/haematol.2010.036277","article-title":"Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis","volume":"96","author":"Ondrejka","year":"2011","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.009_bib7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/modpathol.2017.135","article-title":"CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course","volume":"31","author":"Hu","year":"2018","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.009_bib8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13046-017-0652-8","article-title":"Smoldering mantle cell lymphoma","volume":"36","author":"Ye","year":"2017","journal-title":"J\u00a0Exp Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.009_bib9","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/sj.leu.2402272","article-title":"Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype","volume":"15","author":"Bernard","year":"2001","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.009_bib10","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/bloodadvances.2019001396","article-title":"Genomic profiles and clinical outcomes of de novo blastoid\/pleomorphic MCL are distinct from those of transformed MCL","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.hoc.2020.06.009_bib11","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the european mantle cell lymphoma network","volume":"34","author":"Hoster","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.hoc.2020.06.009_bib12","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.009_bib13","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302","article-title":"p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis","volume":"87","author":"Greiner","year":"1996","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.009_bib14","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/blood.V87.8.3351.bloodjournal8783351","article-title":"p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas","volume":"87","author":"Hernandez","year":"1996","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2020.06.009_bib15","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2011.162","article-title":"Impact of TP53 mutation and 17p deletion in mantle cell lymphoma","volume":"25","author":"Halldorsdottir","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.009_bib16","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/gcc.22123","article-title":"Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index","volume":"53","author":"Sarkozy","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.009_bib17","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1002\/cncr.31328","article-title":"Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy","volume":"124","author":"Greenwell","year":"2018","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.009_bib18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/his.12760","article-title":"MYC overexpression correlates with MYC amplification or translocation, and is associated with poor prognosis in mantle cell lymphoma","volume":"68","author":"Choe","year":"2016","journal-title":"Histopathology"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.009_bib19","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1038\/leu.2012.72","article-title":"Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease","volume":"26","author":"Royo","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.009_bib20","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/path.1781","article-title":"IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome","volume":"206","author":"Cogliatti","year":"2005","journal-title":"J\u00a0Pathol"},{"issue":"20","key":"10.1016\/j.hoc.2020.06.009_bib21","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.009_bib22","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1349-7006.2009.01433.x","article-title":"Mantle cell lymphoma shows three morphological evolutions of classical, intermediate, and aggressive forms, which occur in parallel with increased labeling index of cyclin D1 and Ki-67","volume":"101","author":"Kimura","year":"2010","journal-title":"Cancer Sci"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.009_bib23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00428-005-0049-5","article-title":"Growth pattern and distribution of follicular dendritic cells in mantle cell lymphoma: a clinicopathological study of 96 patients","volume":"448","author":"Schrader","year":"2006","journal-title":"Virchows Arch"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.009_bib24","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3109\/10428194.2015.1094801","article-title":"Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group Experience","volume":"57","author":"Bhatt","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2020.06.009_bib25","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2018-99-115360","article-title":"Clinical and genomic characteristics in de novo blastoid\/pleomorphic (<em>dn<\/em>MCL) and transformed blastoid\/pleomorphic (t-MCL) mantle cell lymphoma (MCL) in the ibrutinib era: comprehensive analysis of 168 patients","volume":"132","author":"Jain","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.009_bib26","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1097\/PAS.0000000000001312","article-title":"Mantle cell lymphoma involving skin: a clinicopathologic study of 37 cases","volume":"43","author":"Kim","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.009_bib27","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdt139","article-title":"Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network","volume":"24","author":"Cheah","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.009_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/modpathol.3800716","article-title":"Sequence analysis proves clonal identity in five patients with typical and blastoid mantle cell lymphoma","volume":"20","author":"Yin","year":"2007","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.009_bib29","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1101\/mcs.a004259","article-title":"Divergent clonal evolution of a common precursor to mantle cell lymphoma and classic Hodgkin lymphoma","volume":"5","author":"Tashkandi","year":"2019","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.009_bib30","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1309\/TE56-A43X-29TT-5H8G","article-title":"CD5- mantle cell lymphoma","volume":"118","author":"Liu","year":"2002","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.009_bib31","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/PAS.0000000000001278","article-title":"CD5-negative mantle cell lymphoma: clinicopathologic correlations and outcome in 58 patients","volume":"43","author":"Miao","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.hoc.2020.06.009_bib32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.humpath.2019.04.010","article-title":"CD23 expression in mantle cell lymphoma is associated with CD200 expression, leukemic non-nodal form, and a better prognosis","volume":"89","author":"Saksena","year":"2019","journal-title":"Hum Pathol"},{"issue":"9","key":"10.1016\/j.hoc.2020.06.009_bib33","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2018-07-862151","article-title":"CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1(-) mantle cell lymphoma","volume":"133","author":"Martin-Garcia","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.009_bib34","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood.V89.4.1421","article-title":"Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones","volume":"89","author":"Ott","year":"1997","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.009_bib35","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/S0046-8177(03)00412-X","article-title":"Cytogenetic findings in blastoid mantle cell lymphoma","volume":"34","author":"Khoury","year":"2003","journal-title":"Hum Pathol"},{"issue":"45","key":"10.1016\/j.hoc.2020.06.009_bib36","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Bea","year":"2013","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.009_bib37","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2020.06.009_bib38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2019-129563","article-title":"Genomic profiling of mantle cell lymphoma suggests poor-risk profile is present at diagnosis and does not arise by tumor evolution","volume":"134","author":"Joffe","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.009_bib39","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/PAS.0000000000000758","article-title":"Mantle cell lymphoma With MYC rearrangement: a report of 17 patients","volume":"41","author":"Hu","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"491","key":"10.1016\/j.hoc.2020.06.009_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau1167","article-title":"Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.009_bib41","doi-asserted-by":"crossref","first-page":"12857","DOI":"10.1038\/s41598-019-49326-3","article-title":"Classification of aggressive and classic mantle cell lymphomas using synchrotron Fourier Transform Infrared microspectroscopy","volume":"9","author":"Kolodziej","year":"2019","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.009_bib42","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"122","author":"Jares","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"21","key":"10.1016\/j.hoc.2020.06.009_bib43","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.4161\/cc.8.21.9977","article-title":"p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA","volume":"8","author":"Hedstrom","year":"2009","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.009_bib44","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.V89.1.272","article-title":"Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas","volume":"89","author":"Pinyol","year":"1997","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.009_bib45","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood-2008-03-142182","article-title":"Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma","volume":"112","author":"Chen","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2020.06.009_bib46","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3324\/haematol.2011.055715","article-title":"The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index","volume":"97","author":"Slotta-Huspenina","year":"2012","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.009_bib47","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.semcdb.2004.11.008","article-title":"The role of the AU-rich elements of mRNAs in controlling translation","volume":"16","author":"Espel","year":"2005","journal-title":"Semin Cell Dev Biol"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.009_bib48","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1182\/blood-2006-08-039859","article-title":"Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival","volume":"109","author":"Wiestner","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.009_bib49","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood-2017-02-767293","article-title":"Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia","volume":"130","author":"Zhang","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.009_bib50","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.009_bib51","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.ccell.2016.09.014","article-title":"Decoding the DNA methylome of mantle cell lymphoma in the light of the entire B cell lineage","volume":"30","author":"Queiros","year":"2016","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.009_bib52","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/leu.2011.305","article-title":"The miRNA-17 approximately 92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K\/AKT pathway activation","volume":"26","author":"Rao","year":"2012","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.hoc.2020.06.009_bib53","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1182\/blood-2014-06-584193","article-title":"miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator","volume":"125","author":"Husby","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.009_bib54","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3892\/ijo.2015.3295","article-title":"Identification of miR-15b as a transformation-related factor in mantle cell lymphoma","volume":"48","author":"Arakawa","year":"2016","journal-title":"Int J Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.009_bib55","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/path.1254","article-title":"Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression","volume":"199","author":"Khoury","year":"2003","journal-title":"J\u00a0Pathol"},{"issue":"10044","key":"10.1016\/j.hoc.2020.06.009_bib56","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.009_bib57","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of Older Patients with Mantle-Cell Lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.hoc.2020.06.009_bib58","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1182\/blood-2017-08-737502","article-title":"Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!","volume":"132","author":"Dreyling","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.009_bib59","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized european MCL elderly trial","volume":"38","author":"Kluin-Nelemans","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.009_bib60","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC\u00a0+ autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.009_bib61","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"issue":"28","key":"10.1016\/j.hoc.2020.06.009_bib62","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.009_bib63","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies","volume":"179","author":"Rule","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.009_bib64","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.15411","article-title":"Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"182","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.009_bib65","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1038\/s41375-019-0575-9","article-title":"Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma","volume":"33","author":"Wang","year":"2019","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.hoc.2020.06.009_bib66","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.009_bib67","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.009_bib68","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.009_bib69","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T\u00a0cells with fully human binding domains in patients with B-cell lymphoma","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.009_bib70","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdv074","article-title":"Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL)","volume":"26","author":"Chihara","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.009_bib71","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/annonc\/mdm447","article-title":"Central nervous system involvement in mantle cell lymphoma","volume":"19","author":"Ferrer","year":"2008","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.hoc.2020.06.009_bib72","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1182\/blood-2015-05-647834","article-title":"Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse","volume":"126","author":"Bernard","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.009_bib73","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"issue":"S2","key":"10.1016\/j.hoc.2020.06.009_bib74","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/hon.12_2629","article-title":"Ibrutinib with rituximab (ir) and short course r-hypercvad\/mtx is very efficacious in previously untreated young pts with mantle cell lymphoma (MCL)","volume":"37","author":"Wang","year":"2019","journal-title":"Hematol Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.009_bib75","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.009_bib76","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjh.13796","article-title":"Rituximab plus hyper-CVAD alternating with MTX\/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center","volume":"172","author":"Chihara","year":"2016","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.hoc.2020.06.009_bib77","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in\u00a0vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.hoc.2020.06.009_bib78","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909","volume":"27","author":"Damon","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.009_bib79","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/bloodadvances.2019001355","article-title":"Rituximab\/bendamustine and rituximab\/cytarabine induction therapy for transplant-eligible mantle cell lymphoma","volume":"4","author":"Merryman","year":"2020","journal-title":"Blood Adv"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:14:48Z","timestamp":1760184888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820300721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":79,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0889858820300721"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.06.009","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blastoid Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}